For decades, standard regimens based on corticosteroids and classic immunosuppressive agents have become the main therapy for patients with immune-mediated glomerular diseases, but some patients had poor efficacy or intolerance to these classic drugs. The emergence of new biological agents has brought dawn to the targeted treatment of such diseases, and is of great significance in improving patients′ clinical symptoms and quality of life. However, the treatment options, the effectiveness, and safety of the treatment have yet to be further refined by large randomized controlled trials. This article reviewed the application progress of the widely used new biological agents like rituximab, belimumab, eculizumab, and bortezomib in the treatment of kidney diseases.